HomeTrialNCT02932150
🔬NCT02932150Phase 2RECRUITING

Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection

Study Summary

The goals of this clinical study are to compare the effectiveness, safety and tolerability of study drug, tenofovir alafenamide (TAF), versus placebo in teens and children with CHB and to learn more about the dosing levels in children.

Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment150 participants
Primary Completion
Lead SponsorGilead Sciences
Data Retrieved2026-04-11 02:55:27.113363+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.